Burjeel Holdings Reports 129% IncreaseQ2’25 Net Profit, with Accelerated Revenue Growth

Abu Dhabi, United Arab Emirates, 7 August 2025: Burjeel Holdings PLC (“Burjeel” or “the Group”), a
leading super-specialty healthcare services provider in MENA listed on the Abu Dhabi Securities
Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), today announced its financial results in
accordance with International Financial Reporting Standards (IFRS) for the three-month and six-month
periods ended 30 June 2025.

groundbreaking research in microgravity, aiming to transform care for patients with diabetes in space and
on Earth.
John Sunil, Chief Executive Officer of Burjeel Holdings, said:
“The second quarter delivered exceptionally strong results, with 19% revenue growth driven by a 12%
increase in patient footfall and improved yield. EBITDA rose by 59%, accompanied by a margin uplift to
22%. This robust performance significantly strengthened the first-half outcome, underscoring Burjeel
Holdings’ resilience and long-term sustainable growth.
“These results reflect tangible progress in key operational areas such as physician manpower
optimization, formulary management, and cost control, while our strategic focus on super-specialty care is
beginning to yield measurable benefits, enhancing both revenue and profitability. We continue to invest in
high-value services and next-generation care facilities to support long-term momentum.
“We also advanced key strategic priorities, reinforcing leadership in complex care across oncology,
transplants, fertility, mental health, and diagnostics. Our oncology platform is now the UAE’s largest
private network, featuring new cancer clinics and cell and gene therapy capabilities. The Alkalma mental

health platform is scaling regionally, alongside rehabilitation services through over 30 PhysioTherabia
centers in Saudi Arabia. Additionally, we introduced the region’s first Osseointegration Clinic for cutting-
edge prosthetic care.
“In parallel with expanding our network of primary care and medical centers, we deepened partnerships
with government and corporate stakeholders and accelerated digital integration through Oracle Health
EMR and AI-powered tools. Building on this platform, we entered into pivotal partnerships in oncology,
value-based care, diagnostics, and international healthcare innovation, establishing the Group as the
healthcare partner of choice.
“Burjeel Holdings is uniquely positioned to capture significant opportunities across the region, supported
by rising demand for complex care and a growing population. Our focus remains on converting recent
investments into sustained expansion and margin improvement, while maintaining disciplined financial
management to support long-term shareholder value. Net profit growth of 129% in the reporting quarter
reinforces this trajectory and strengthens the foundation for consistent shareholder returns.”
Q2’25: Growth Delivered, Efficiency Embedded
Burjeel Holdings delivered strong top-line growth of 18.7% to AED 1,403 million in Q2’25, driven by
a 12.1% increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched
facilities across the network. Revenue in H1’25 rose 12.2% to AED 2,677 million, with total patient visits
reaching 3.4 million.
Oncology remained a core growth driver, with revenue rising 36.7% in Q2’25 and 38.1% in H1’25,
underpinned by oncology network expansion and improved conversion in surgical and advanced
therapies. Other specialties also recorded solid gains in H1’25, including urology (+18%), emergency
medicine (+17%), cardiology (+16%), and gastroenterology (+13%).
Inpatient footfall rose 17.7% in Q2’25, reflecting strong demand across key specialties and a ramp-up
in elective surgeries post-Ramadan. The Group performed 22,930 surgeries, up 18.7%, with momentum
concentrated at Burjeel Medical City, Burjeel Specialty Hospital Sharjah, Lifecare Hospital Musaffah and
Burjeel Royal Hospital Al Ain. Bed occupancy improved to 69%, up from 65% a year ago, and averaged
69% in H1’25. Inpatient volumes rose 14.6% over the first half.
Outpatient footfall grew 12.0% in Q2’25, accelerating from 5.2% in Q1, driven by primary care and
physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family
medicine. Utilization improved to 68%, up from 65% in Q1’25, enabled by optimized hiring and scaling of
clinical teams. Leading facilities included Burjeel Medical City, Lifecare Hospital Baniyas, and Burjeel Day
Surgery Center Barari. In H1’25, outpatient volumes increased 8.6%.
EBITDA rose 59.4% to AED 306 million in Q2’25, fueled by strong revenue growth, enhanced physician
productivity, and better performance across recently ramped-up assets. This includes AED 72 million in
gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The EBITDA
margin expanded 5.6 p.p. to 21.8%. In H1’25, EBITDA increased 14.2% to AED 487 million, with a margin
of 18.2%.
Net profit surged 128.9% to AED 148 million in Q2’25, reflecting margin expansion, enhanced
operating leverage, and asset optimization. In H1’25, net profit rose 10.6% to AED 187 million.
Hospitals Lead Growth, Medical Centers Accelerate
The Hospitals segment continued to drive Group performance, contributing 89% of total revenue in
Q2’25. Revenue grew 17.3% to AED 1,245 million, supported by strong growth in patient volumes and
sustained demand for complex care services. Segment EBITDA rose by 40.6%, led by strong
performance across key hospitals, including Burjeel Medical City, Burjeel Hospital Abu Dhabi, Burjeel Day
Surgery Center Barari and Burjeel Royal Hospital Al Ain.

The Medical Centers segment also delivered exceptional growth, with Q2’25 revenue rising 36.8% to
AED 121 million. This was driven by the successful ramp-up of over 45 new centers across the UAE and
Saudi Arabia, expanding access to high-quality outpatient and physiotherapy services. In H1’25, Medical
Centers revenue increased 26.7% to AED 229 million, reflecting the Group’s strong momentum in scaling
primary care.
BMC: Scaling Patient Base & Driving Efficiency Gains
Burjeel Medical City (BMC), the Group’s flagship facility, remained a key growth engine, achieved
14.7% growth in revenue to AED 333 million, driven by a 30.4% increase in patient volumes. This
performance was underpinned by a higher outpatient share, strong oncology momentum, and robust
post-Ramadan demand for minimally invasive and elective procedures. Bed occupancy improved to 68%,
underscoring stronger inpatient utilization. Revenue from BMC in H1’25 increased 13.0% to AED 648
million.
BMC EBITDA rose 21.3% to AED 59 million in Q2’25, with the EBITDA margin improving to 17.6%. In
H1’25, EBITDA grew 20.8% YoY to AED 112 million, with margin expansion of 1.1 p.p. to 17.3%.
Profitability growth was supported by scale efficiencies and continued investment in super-specialty
services. BMC’s performance reinforces its strategic role as the Group’s key platform for complex care
and future value creation.

Disciplined Leverage with Strong Cash Generation
Operating cash flow increased 8.1% YoY in H1’25, driven by improved operational performance and
disciplined working capital management. Maintenance CAPEX remained in line with guidance, while
Growth CAPEX totaled AED 403 million, driven by strategic M&A activities and ongoing network
expansion. Free cash flow (FCF) 1 conversion improved to 54% in H1’25.
The Group’s net debt / pre-IFRS 16 LTM EBITDA 2 stood at 1.8x as of 30 June 2025, reflecting the
acquisition of the Dubai hospital building. This strategic transaction enhanced asset ownership while
optimizing the Group’s cost structure.
The Group maintains a strong and flexible balance sheet, enabling continued investment in growth
opportunities. With no contingent off-balance sheet liabilities, management remains focused on optimizing
capital structure through debt reduction, refinancing, and tenure extension.
Dividend Policy
Burjeel Holdings is committed to delivering value to stakeholders while ensuring alignment with
strategic growth plans. The Group maintains a dividend policy with a payout range of 40–70% of net
income, depending on investment needs for expansion.
In May 2025, the Group declared a full-year dividend of AED 170 million for FY2024, representing
47% of net profit. This reflects strong profitability and a balanced approach to rewarding shareholders
while supporting long-term growth.

maintenance CAPEX – change in working capital. Working capital = inventory + receivables – payables (incl.
accruals). Change in working capital is calculated as working capital balance in prior period less working capital balance in current
period. (2) Net debt / pre-IFRS 16 EBITDA is calculated as reported EBITDA less annual lease rental payments, and net debt is
calculated as bank debt less cash and bank balances. (3) OPEX refers to total operating expenses excluding all depreciation &
amortization expenses and one-offs. (4) EBITDA is calculated as profit for the period before income tax expense, finance costs,
depreciation & amortization, and interest income from related parties.

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE
and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group
operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and
quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its
network comprises 112 assets across the UAE, Oman, and Saudi Arabia, including 20 hospitals, 37
medical centers, 30 physiotherapy and wellness centers, 15 pharmacies, and 10 other allied services.
Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia, Alkalma, and Tajmeel.